



Mehrdad Zeinalian

MD, MPH, PhD

Assistant Professor in Department of Genetics & Molecular biology, School of Medicine,
Isfahan University of Medical Sciences

Education

MD: Shahrekord University of Medical Sciences, Shahrekord, Iran (1992-1999)

MPH: Iran University of Medical Sciences, Tehran, Iran (2006-2009)

PhD: Shahrekord University of Medical Sciences, Shahrekord, Iran (2011-2015)

Professional Experiences

- A) Manager of Rural Health Centers in Isfahan Province (2000-2004)
- B) Manager of Urban & District Health Centers: Dehaghan district, Isfahan Province (2004-2005)
- D) Manager of Provincial Non-Communicable Diseases Programs: Center for Control diseases, Esfahan Provincial Health Center (2005-2011)
- C) Coordinator and executive manager of prevention and control project on Diabetes & Hemophilia in Isfahan Province (2005-2007)
- D) Scientific head of Cancer Genetic Counseling and Prevention unit in MACSA (Ala Cancer Prevention and Control Center, Isfahan, Iran) (2012- current)
- E) PhD project (Molecular Analysis of familial colorectal cancers at-risk for Lynch syndromes) (2011-2015)
- F) Assistant Professor in Department of Genetics & Molecular biology, School of Medicine, Isfahan University of Medical Sciences (2015-current)
- G) Editorial Board Member of Clinical Research Committee in Isfahan University of Medical Sciences (2016-2018)
- H) Editorial Board Member of Basic Sciences Publication Committee in Isfahan University of Medical Sciences (2016-current)
- I) Editorial Board Member of Research Ethics Committee in Isfahan University of Medical Sciences (2018-current)
- J) Technical Manager of Health deputy, Isfahan University of Medical Sciences (2021-current)

Publications

- 1) **Zeinalian M**, Moafi AR, Fadaie Nobari R , Heidari K. Introduction of a new index to compare function of screening labs of thalassemia prevention program in Isfahan province. *Blood*. 2009; 6(2): 131-139.
- 2) **Zeinalian M**, Samvat A, Fadaie Nobari R , Azin SA. Incidence rate of major beta-thalassemia and study of its causes after prevention and control program of thalassemia in Isfahan Province. *Blood*. 2009; 6(4): 238-247.
- 3) Moafi AR, Valian S, Nikyar Z, **Zeinalian M**, Momenzadeh M, Rahgozar S. Prevalence of Minor β-thalassemia Based on RBC Indices among Final Suspected Individuals in Premarital Screening Program Referred to Genetic Laboratories. *International Journal of Hematology-Oncology and Stem Cell Research* 2010. 4(1):23-27.
- 4) **Zeinalian M**, Fadaei Nobari R, Ramazanpour J. Epidemiological features of human brucellosis in central Iran, 2006-2011. *Public Health*. 2012;126(12):1058-62.
- 5) **Zeinalian M**, Nobari RF, Moafi A, Salehi M, Hashemzadeh-Chaleshtori M. Two decades of pre-marital screening for beta-thalassemia in central Iran. *J Community Genet*. 2013; 4(4):517-22.
- 6) **Zeinalian M**, Moafi AR, Fadayi-Nobari R. A study to evaluate the results of pre-marital screening program for beta-thalassemia in Isfahan province, 1997-2010. *Scientific Journal of Iranian Blood Transfusion Organization*. 2013; 10 (1)
- 7) **Zeinalian M**, Merghati-Khoei E, Azin SA, Hashemzadeh-Chaleshtori M. Help-seeking Behaviours among Haemophilia Community in Central Iran: A Qualitative Study. *J Blood Disorders*. 2014; Transf 5:214. doi: 10.4172/2155-9864.1000214
- 8) **Zeinalian M**, Emami MH, Naimi A, Salehi R, Hashemzadeh-Chaleshtori M. Immunohistochemical analysis of mismatch repair proteins in Iranian colorectal cancer patients at risk for lynch syndrome. *Iran J Cancer Prev*. 2015; 8(1):11-7.
- 9) **Zeinalian M**, Hashemzadeh-Chaleshtori M, Salehi R, Kazemi M, Emami MH. Tumor microsatellite instability and clinicopathologic features in Iranian colorectal cancer patients at risk for Lynch syndrome. *J Res Med Sci* 2015;20:154-60.
- 10) **Zeinalian M**, Emami MH, Salehi R, Naimi A, Kazemi M, Hashemzadeh-Chaleshtori M. Molecular Analysis of Iranian Colorectal Cancer Patients at Risk for Lynch Syndrome: a New Molecular, Clinicopathological Feature. *J Gastrointest Cancer*. 2015 Feb 27. [Epub ahead of print] PMID:25722176
- 11) **Zeinalian M**, Hashemzadeh-Chaleshtori M, Akbarpour MJ, Emami MH. Epidemioclinical Feature of Early-Onset Colorectal Cancer at-Risk for Lynch Syndrome in Central Iran. *Asian Pac J Cancer Prev*. 2015;16(11):4647-52.
- 12) **Zeinalian M**, Eshaghi M, Naji H, Marandi SMM, Sharbafchi MR, Asgari S. Iranian-Islamic traditional medicine: An ancient comprehensive personalized medicine. *Adv Biomed Res*. 2015;4:191.
- 13) **Zeinalian M**, Heidarzadeh N, Naji H, Sharbafchi MR. Clinicopathological Analysis of Patients with Breast Cancer and Their Families. *IJBC* 2016; 8(1):17-22.
- 14) **Zeinalian M**, Eshaghi M, Naji H, Marandi SMM, Sharbafchi MR, Asgari S. A comparative study on cancer prevention principles between Iranian traditional medicine and classic medicine. *Int J Prev Med*. 2016;7:61.
- 15) **Zeinalian, M.**, Hadian, M., Hashemzadeh-Chaleshtori, M., Salehi, R. and hassan Emami, M., 2016. Familial colorectal cancer type X in Central Iran: a new clinicopathologic description. *International Journal of Hematology-Oncology and Stem Cell Research*.
- 16) Farahani N, Nikpou P, Emami MH, Hashemzadeh M, **Zeinalian M**, Shariatpanahi SS, Salehi R. Evaluation of MT1XT20 Single Quasi-Monomorphic Mononucleotide Marker for Characterizing Microsatellite Instability in Persian Lynch Syndrome Patients. *Asian Pacific journal of cancer prevention: APJCP*. 2016;17(9):4259.
- 17) **Zeinalian M**, Eshaghi M, Hadian M, Naji H, Marandi SMM, Asgari S. Eight essential foods in Iranian traditional medicine and their role in health promotion and well-being. *Int J Prev Med*. 2017; 8:2.

- 18) Babaei H, **Zeinalian M**, Emami MH, Hashemzadeh M, Farahani N. Simplified microsatellite instability detection protocol provides equivalent sensitivity to robust detection strategies in Lynch syndrome patients. *Cancer Biology & Medicine* 14 (2), 142-150
- 19) **Zeinalian M**, Eshaghi M, Naji H, Marandi SMM, Asgary S. Constipation in Iranian-Islamic Traditional Medicine: The Origin of Diseases. *Health Scope*. In Press(In Press):e64017
- 20) Moridnia A, Tabatabaiefar MA, **Zeinalian M**, Minakari M, Kheirollahi M. Novel Variants and Copy Number Variation in *CDH1* Gene in Iranian Patients with Sporadic Diffuse Gastric Cancer. *Journal of gastrointestinal cancer*, 2018; 1-8
- 21) Emami A, Tajadini M, **Zeinalian M**, Keshvari M, Asgary S. Paraoxonase 1 activities and its gene promoter single nucleotide polymorphisms (-108,-126, and -162) in diabetes mellitus. *Interventional Medicine and Applied Science*, 2018; 1-6
- 22) **Zeinalian M**, Hashemzadeh-Chaleshtori M, Salehi R, Emami MH. Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer. *Advanced biomedical research*. 2018; 7
- 23) **Zeinalian M**, Eshaghi M, Hadian M, Naji H, Asgary S. Personalized nutrition: An ancient concept in Iranian traditional medicine. *International Journal of Preventive Medicine*, 2019; 10 (1): 94
- 24) Moridnia A, Tabatabaiefar MA, **Zeinalian M**, Minakari M, Kheirollahi M. Novel Variants and Copy Number Variation in *CDH1* Gene in Iranian Patients with Sporadic Diffuse Gastric Cancer .*Journal of gastrointestinal cancer*, 2019; 50 (3), 420-427
- 25) **Zeinalian M**, Salari-Jazi A, Jannesari A, Khanahmad H. A potential protective role of losartan against coronavirus-induced lung damage. *Infection Control & Hospital Epidemiology*, 2020; 41 (6), 752-753
- 26) Fakhrolmobasher M, Nasr-Esfahany Z, Khanahmad H, **Zeinalian M**. Selenium supplementation can relieve the clinical complications of COVID-19 and other similar viral infections. *International Journal for Vitamin and Nutrition Research*, 2020; 1 (1), 1-3
- 27) **Zeinalian M**, MH Emami, MR Pourreza, et al. Somatic BRAF V600E Mutation in Familial Colorectal Cancer Type X: A New Study in Central Iran. *entashapir Journal of Cellular and Molecular Biology*: 12 (2); e115099
- 28) Norouzi M, Shafiei M, Abdollahi Z, Miar P, Galehdari H, Emami MH, **Zeinalian M** and Tabatabaiefar MA (2021) WRN Germline Mutation Is the Likely Inherited Etiology of Various Cancer Types in One Iranian Family. *Front. Oncol.* 11:648649. doi: 10.3389/fonc.2021.648649
- 29) Azardoost H , Rahimi F, **Zeinalian M**, Rezayatmand R. Cost-Effectiveness Analysis of Molecular Screening to Identify Lynch Syndrome in the Patients with Colorectal Cancer, *Int J Cancer Manag*. 2021 14(4): e108198. doi: 10.5812/ijcm.108198.
- 30) Kouhpayeh S, Shariati L, Boshtam M, **Zeinalian M**, et al. The molecular basis of covid-19 pathogenesis, conventional and nanomedicine therapy. *Int. J. Mol. Sci.* 2021, 22(11), 5438; <https://doi.org/10.3390/ijms22115438>
- 31) Fakhrolmobasher M, Shiravi A, **Zeinalian M**. SARS-CoV-2 interaction with human DNA methyl transferase 1: A potential risk for increasing the incidence of later chronic diseases in the survived patients. *International Journal of Preventive Medicine*. 2022; 13 (1), 23.
- 32) Rahimi F, **Zeinalian M**, Rezayatmand R. Rapid Health Technology Assessment of Oncotype DX in Patients with Early-Stage Breast Cancer. *Iranian Quarterly Journal of Breast Disease*. 2022; 14 (4), 75-93.

Presentations

- 1) Epidemiologic feature of beta-thalassemia in Isfahan Province. 11th Iranian Genetics Congress. May 2010. Tehran. Iran
- 2) Health Promotion Congress. March 2010. Chabahar. Iran
- 3) The First International & 4th National congress on HEALTH EDUCATION & PROMOTION. May 2011. Tabriz. Iran
- 4) Evaluation of the incidence of major beta-thalassemia and its causes after pre-marriage screening program of thalassemia in Isfahan Province (Iran). 26th International Pediatric Association Congress of Pediatrics. August 2010. Johannesburg. South Africa
- 5) An Epidemiologic survey on Brucellosis among children in Isfahan Province (IR Iran). 26th International Pediatric Association Congress of Pediatrics. August 2010. Johannesburg. South Africa
- 6) Pre-marriage Screening Program for Beta-Thalassemia in Isfahan (center of Iran) (2005-2010). European Conference of Human Genetics 2011. May 2011. Amsterdam RAI. the Netherlands
- 7) Epidemiological Feature of Human Brucellosis in central part of Iran (2006-2009). Communicable Disease Control Conference 2011. Canberra. Australia
- 8) Clinical aspects of microsatellite instability testing in colorectal cancer: a systematic review. 1th International Congress of GI cancers. December 2014. Tehran. Iran
- 9) Genetic counseling for breast cancer patients and their at-risk families in Isfahan: a clinicopathological description. Cancer and Prevention Conference. January 2015. Tehran. Iran
- 10) Cancer prevention and treatment according to Iranian-Islamic traditional medicine: an ancient comprehensive attitude. International Congress of Cancer therapy. Sep 2015. Atlanta, USA
- 11) Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome. International Congress of Digestive disease. Dec 2015. Nanjing, China
- 12) BRAF gene mutation in Iranian familial colorectal cancer patients at risk for Lynch syndrome. Iranian Congress of Gastroenterology and Hepatology. Nov 2017. Tehran. Iran
- 13) A comprehensive model for cancer prevention and early detection. International Iranian Personalised Medicine. Jan 2018. Tehran. Iran
- 14) A novel stop-gain mutation in the *MSH2* gene among a Persian family fulfilling classic Amsterdam criteria for Lynch syndrome. International Iranian Personalised Medicine. Jan 2018. Tehran. Iran
- 15) Familial osteosarcoma in a large pedigree: A case Report. International Iranian Personalised Medicine. Jan 2018. Tehran. Iran
- 16) Cancer Genetic Counseling: A family-centered experience for palliative care in cancer. World Congress in Gerontology and Palliative care. Aug 2018. Paris. France